FHIR CI-Build

This is the Continuous Integration Build of FHIR (will be incorrect/inconsistent at times).
See the Directory of published versions icon

4.3.2.146 CodeSystem http://hl7.org/fhir/protein-modification-type

Responsible Owner: Biomedical Research and Regulation icon Work Group Informative Use Context: Country: World, Not Intended for Production use
Official URL: http://hl7.org/fhir/protein-modification-type Version: 6.0.0-ballot4
active as of 2026-06-30 Computable Name: ProteinModificationTypeExample
Flags: Experimental, CaseSensitive, Complete. All codes ValueSet: Protein Modification Type OID: TBD

This Code system is used in the following FHIR core-defined or referenced value sets:

4.3.2.146.1 Definition

A high-level summary of how a protein has been modified, e.g. PEGylation, lipidation, Fc fusion. Useful for categorising modified biologics without enumerating the detailed chemistry.

4.3.2.146.2 Content

Generated Narrative: CodeSystem protein-modification-type

Last updated: 2026-07-04T18:53:58.933Z

This case-sensitive code system http://hl7.org/fhir/protein-modification-type defines the following codes:

CodeDisplayDefinitionCopy
PEGylated PEGylated Conjugated to one or more polyethylene glycol (PEG) chains for half-life extension. Examples: pegfilgrastim, peginterferon, certolizumab pegol. btn btn
lipidated Lipidated Conjugated to a fatty acid chain (acylation) for half-life extension via albumin binding. Examples: semaglutide, liraglutide, insulin detemir, insulin degludec. btn btn
Fc-fused Fc fusion Fused to an immunoglobulin Fc region for half-life extension and effector function. Examples: etanercept, abatacept, aflibercept, dulaglutide. btn btn
albumin-fused Albumin fusion Fused to human serum albumin for half-life extension. Example: albiglutide. btn btn
drug-conjugated Drug-conjugated (ADC) Conjugated to a small-molecule drug payload via a linker (antibody-drug conjugate). Examples: trastuzumab emtansine, brentuximab vedotin, gemtuzumab ozogamicin. btn btn
polysaccharide-conjugated Polysaccharide-conjugated Conjugated to a polysaccharide antigen for vaccine immunogenicity. Examples: Hib, pneumococcal and meningococcal conjugate vaccines. btn btn
glycoengineered Glycoengineered Glycan structure engineered (e.g. afucosylated) to alter biological activity. Examples: obinutuzumab, mogamulizumab (enhanced ADCC). btn btn
amino-acid-substituted Amino acid substituted Sequence carries one or more amino acid substitutions relative to a natural or parent protein. Examples: insulin analogs lispro, aspart, glargine. btn btn
truncated Truncated Sequence is shortened relative to the parent protein. btn btn
biotinylated Biotinylated Covalently labelled with biotin. Typical for research or diagnostic reagents. btn btn
fluorescent-labeled Fluorescent labelled Covalently labelled with a fluorescent dye. Typical for imaging or flow-cytometry reagents. btn btn

 

See the full registry of code systems defined as part of FHIR.

Explanation of the columns that may appear on this page:

Level A few code lists that FHIR defines are hierarchical - each code is assigned a level. See Code System for further information.
Source The source of the definition of the code (when the value set draws in codes defined elsewhere)
Code The code (used as the code in the resource instance). If the code is in italics, this indicates that the code is not selectable ('Abstract')
Display The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application
Definition An explanation of the meaning of the concept
Comments Additional notes about how to use the code